



Cite this: DOI: 10.1039/d4pm00215f

# Preparation and characterization of efavirenz cocrystal-encapsulated pronanoliposomes for antiretroviral therapy with improved bioavailability†

Sucheta Sarkar,  Arijit Prosad Roy, Sanchita Mitra, Gouranga Nandi,   
Ranabir Sahu, Tarun Kumar Dua  and Paramita Paul \*

The present research work aims to improve the bioavailability of the antiretroviral drug efavirenz (EFV) using pharmaceutical cocrystallization technique. EFV is a potential antiretroviral drug that exhibits extremely poor water solubility and poor oral bioavailability and falls under the BCS-II category. EFV and L-proline were selected in a 1 : 1 equimolar ratio to formulate efavirenz proline co-crystals, and a facile method was adopted to prepare co-crystals of EFV. The formation of a new solid phase was confirmed through advanced techniques such as Fourier-transform infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC) and powder X-ray diffraction (pXRD) analysis, and solubility study was conducted utilising UV visible spectroscopy. Proliposomal vesicles containing EFV or EFV cocrystals were prepared using thin film hydration methods with few modifications. The vesicle size in dispersion, zeta potential, surface morphology, drug loading and *in vitro* drug release were assessed. Co-crystallization increased the solubility of EFV up to 3 fold, and the liposomes were found to release the drug in a sustained manner. The optimized formulation was found to have a substantial amount of EFV loading (32.70%) and entrapment efficiency (99.28%) with a narrow range of size distribution. The liposomes containing the pure drug showed 72% release of the drug in 72 h, whereas the liposomes containing co-crystals showed 99.98% release of the drug in 72 h. This was due to the presence of L-proline in association with EFV, which led to an enhancement in the polarity of hydrophobic EFV, thus increasing its dissolution in drug release media. The present work reports a cost-effective method for the enhancement of drug solubility, providing sustained drug release from liposome and thereby improving the oral bioavailability of the anti-viral agent EFV.

Received 23rd July 2024,  
Accepted 3rd December 2024

DOI: 10.1039/d4pm00215f

rsc.li/RSCPharma

## Introduction

Acquired immunodeficiency syndrome (AIDS) caused by the human immunodeficiency virus (HIV) is a life-threatening infectious disease and is a challenge to public health by virtue of its easy transmissibility.<sup>1</sup> According to the United Nations, over 36.9 million people in the world are living with HIV/AIDS, including 1.8 million children.<sup>2</sup> HIV is transmitted through contact of infected body fluids with mucosal tissue, blood or broken skin. Factors that increase the infectiousness of a person infected with HIV include high levels of the virus in

plasma<sup>3</sup> or genital secretions<sup>4</sup> and other sexually transmitted infections.<sup>5</sup> HIV attacks and destroys CD4<sup>+</sup> T cells, which are the essential component of the immune system, hence leading to knockdown of the immune system.<sup>6</sup> HIV patients are mostly treated with highly active antiretroviral therapy (HAART), which entails frequent administration of multiple antiretroviral (ARV) drugs such as abacavir, efavirenz, zidovudine, lamivudine, and doravirine.<sup>7</sup> Unfortunately, this therapy only improves the quality of the affected person's life by slowing down the replication of the virus within infected cells.<sup>8</sup> Moreover, owing to the lengthy drug administration regimen in HAART and severe adverse effects associated with ARV drugs, patients often do not adhere to it, which leads to the development of drug resistance and, ultimately, therapeutic failure.<sup>9</sup> ARV drugs exhibit poor oral bioavailability due to hepatic first pass metabolism and short biological half-life, and this in fact raises further concerns as it necessitates frequent administration of high doses, which leads to low patient

Department of Pharmaceutical Technology, University of North Bengal, Darjeeling, West Bengal-734013, India. E-mail: paramita37@gmail.com, paramita37@nbu.ac.in; Tel: +919831424214

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4pm00215f>



compliance.<sup>10</sup> Since ARVs remain pivotal to the HAART regimen, there is an urgent need to improve the pharmacological profiles of existing ARVs.<sup>11</sup>

The U.S. Food and Drug Administration (USFDA) has authorized efavirenz (EFV) as a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. However, the limited water solubility of EFV necessitates high dose (maximum 800 mg daily) administration to achieve therapeutic activity.<sup>12,13</sup> As a result, several adverse effects associated with EFV, including insomnia, liver failure, severe rash, nausea, diarrhoea, confusion, depression, hallucination and serious psychiatric effects such as suicidal ideation, are often observed.<sup>14,15</sup> In recent times, pharmaceutical co-crystals have attracted much attention of the formulation scientists. Co-crystals are multiple component crystals or crystalline complexes stabilized by different types of interaction, including hydrogen bonding,  $\pi$ -stacking, and van der Waals forces. Cocrystallization of a drug with a suitable cofomer is one of the many approaches for improving the pharmaceutical performances of a drug, including solubility, dissolution profile, pharmacokinetics, and stability.<sup>16</sup> A variety of molecules can act as cofomers, such as tartaric acid, adipic acid,<sup>17</sup> DL-alanine, oxalic acid, maleic acid, nicotinamide,<sup>18</sup> L-proline,<sup>19</sup> *etc.* Also proline is found to be an effective cofomer with other drugs such as diclofenac,<sup>20</sup> ezetimibe<sup>21</sup> and many others. Among all cofomers, L-proline was available in our lab, and is a water soluble molecule. Studies showed that L-proline effectively enhanced the solubility of many BCS class II drugs. Hence, it was selected as a cofomer.

Pronanoliposomes are a free-flowing solid dispersion formulation of phospholipids, which form nanoliposomal vesicular dispersion in contact with an aqueous phase. These pronanoliposomes could be a promising approach to avoid fusion, aggregation, and sedimentation types of physicochemical instability generally found with liposome formulations and can be used to improve the stability as well as bioavailability of many drugs with poor oral bioavailability performance.<sup>22</sup> Liposomes prepared with dimyristoylphosphatidylcholine and distearoyl-phosphatidylcholine containing EFV and glutathione have been found to enhance the uptake and reduce the cytotoxicity of EFV in the presence of glutathione.<sup>23</sup> Liposomes have been adopted as an approach for many poorly water-soluble drugs.<sup>24,25</sup> Here, we prepared co-crystals of EFV using L-proline to improve the solubility and dissolution rate of the pure drug without affecting its intact structure.<sup>19</sup> This type of work has not been reported earlier and its novelty relies on designing a nanocarrier, such as liposomes, to increase the solubility of EFV and enable targeted and controlled distribution of the ARV drug, which could enhance the molecule's bioavailability and lessen its adverse effects. Liposomes are small artificial vesicles of spherical shape prepared using phospholipids and cholesterol (CHL), and have been extensively studied since the 1960s as delivery systems.<sup>26</sup> By altering the absorption and metabolism, liposomes have increased the therapeutic index of known or newly discovered ARV drugs, leading to a longer plasma half-life and less toxicity.<sup>27</sup> In this

study, we also compare the co-crystal loaded liposomes with the liposomes containing pure EFV.

## Materials and methods

### Materials

Sisco Research Laboratories Private Limited, Mumbai, Maharashtra, India, provided soya lecithin (SLC) (30%) [Batch no. 9175679], CHL [Batch no. 4544907], butylated hydroxytoluene (BHT) [Batch no. 3925242], and L-proline [Batch no. 1979570]. Pristine EFV was gifted by Aurobindo Pharma Limited, Hyderabad, India. Avantor Performance Materials India Ltd, Maharashtra, India, provided disodium hydrogen phosphate. Emplura®, India, provided potassium dihydrogen phosphate, and sodium chloride was provided by Merck Life Science Pvt. Ltd, Mumbai, India. The other chemicals and solvents used in this experiment were all of high analytical grade. Double distilled water was used throughout the experiment and deionised water was used in the DLS study.

### Methods

**Preformulation study.** Preformulation study is performed to examine the characteristics of the pure drug and the excipients of a formulation, as well as to discover any interactions between the drug and the other excipients that will be utilized in the formulation.<sup>28</sup> In the preformulation study, we determine the absorption maxima of EFV in acetonitrile:water in a ratio of 7:3 (v/v) and in phosphate buffer saline (PBS) (pH 7.4) for the purpose of drug loading and drug release, respectively. To detect the interaction between the excipients and the pure form of drug at the functional group level, Fourier transform infrared spectroscopy (FTIR) study was adopted.<sup>29</sup>

**Determination of absorption maxima ( $\lambda_{\max}$ ) of EFV and preparation of the standard curve.** Absorption maxima of EFV were measured in two different media namely PBS, pH 7.4 and a mixture of acetonitrile:water (7:3 (v/v)). PBS, pH 7.4 was used as a medium for the drug release study, and acetonitrile:water (7:3) as the medium for the drug loading study. 1  $\mu\text{g ml}^{-1}$  concentration of the drug solution was prepared in two different solvents and scanned in a UV-visible spectrophotometer (Shimadzu, Japan) with a wavelength range from 200 nm to 400 nm using a fresh solvent (PBS 7.4 and acetonitrile-water mixture in a ratio of 7:3) as the blank solvent. Different drug concentrations were prepared for both solvents to prepare the standard curve, and absorbance was determined using a UV-visible spectrophotometer at a wavelength of maximum absorbance ( $\lambda_{\max}$ ) using a fresh solvent as a blank reference. Then, the absorbance data were plotted against the concentration to get the standard curve. The same process was utilized to prepare a standard curve of EFV in phosphate buffer pH 7.4.

**FTIR spectroscopy.** The chemical interactions between the functional groups of the components used in the formulation were investigated by FTIR spectroscopy. The KBr pellet method was used to scan the pellets over a wavenumber range of 4000–500  $\text{cm}^{-1}$  in the FTIR spectrometer (Compact FTIR



Spectrometer, Alpha II, Bruker, USA) in an inert atmosphere.<sup>30</sup> FTIR spectroscopy of pure components such as pure EFV, L-proline, CHL, SLC, and a physical mixture of EFV with the excipients was performed. Individual components were mixed with anhydrous KBr in a ratio of 1 : 50 (w/w) by using a clean mortar and pestle. The mixture was taken in sufficient amount in a die hole and the punch was placed above it and the set was pressed in a hydraulic press to prepare a transparent pellet. The pellet was then placed in a sample holder and scanned in OPUS software.

**Preparation of co-crystals of EFV.** Co-crystals of EFV were prepared using a facile approach (solvent evaporation method) to increase the solubility of the drug and improve the dissolution profile.<sup>17</sup> Equimolar amounts (1 : 1) of EFV and L-proline were taken in a petri dish. A mixture of two solvents *viz.* acetonitrile and diethyl ether in 1 : 1 (v/v) ratio was added to this. The whole mixture was heated slightly in a water bath to obtain a clear solution and then kept at room temperature for slow evaporation. After evaporation, the co-crystal of EFV was obtained in dry form.<sup>19,31</sup>

### Characterization of the co-crystals

**Solubility study of co-crystals and pure drug.** Since EFV is poorly water soluble, the solubility of EFV cocrystals was checked in water. The solubility study was carried out first in distilled water at 27 °C; an excess amount was added in 10 ml distilled water, and the bottle was screw capped with a stopper. After roughly 24 hours of shaking, the bottle was centrifuged for 15 minutes, and filtered, and 1.2 ml filtrate was diluted up to 10 ml with aqueous ethanol, or ethanol and water (6 : 4); lastly, the sample's absorbance was measured at its corresponding  $\lambda_{\max}$  using a UV-visible spectrometer.<sup>32</sup>

**Preparation of the standard curve of EFV in water.** The same protocol was used for the preparation of the standard curve except that the solvent used was double distilled water. Before getting the absorbance,  $\lambda_{\max}$  of EFV was checked in water. Concentrations of the drug solutions prepared were within the range of 2 to 20  $\mu\text{g ml}^{-1}$ .

**FTIR study of co-crystals.** FTIR of the prepared co-crystals was performed using a previously mentioned method.

**Powder X-ray diffraction (pXRD) analysis.** The pXRD data of L-proline, pure EFV and cocrystal of EFV were recorded in a PANalytical high resolution X-ray powder diffractometer (Malvern PANalytical X'Pert 3, Netherlands) at room temperature (25 °C). Data collection was carried out employing Cu-K $\alpha$  radiation ( $\lambda = 1.5418 \text{ \AA}$ ; 40 kV, 30 mA) as the X-ray source in a 2 $\theta$  continuous scan mode (Bragg-Brentano geometry) in the range of 5–80° at a scan rate of 5°  $\text{min}^{-1}$  and a time of 0.5 s per step. The XRD patterns were plotted and analyzed using X'Pert HighScore Plus software.

**Preparation of liposomes containing pure EFV.** In a round bottom flask (RBF), CHL, SLC, and BHT were dissolved in chloroform (Table 1). The pure drug (100 mg) was added to the solution. Once the entire content was dissolved, it was put on a rotary vacuum evaporator (RVE) (Superfit rotary vacuum evaporator, Superfit Continental Private Limited, India) with the bath temperature maintained at 37 °C and rotated at 120

**Table 1** Composition of different liposomal batches

Formulation code	Form of drug used	EFV <sup>a</sup>	SLC (mg) <sup>b</sup>	CHL (mg) <sup>c</sup>
F1	Pure EFV	100 mg	75	25
F2	Co-crystals of EFV	100 mg	75	25
F3	Pure EFV	100 mg	100	50
F4	Co-crystals of EFV	100 mg	100	50
F5	Pure EFV	100 mg	100	100
F6	Co-crystals of EFV	100 mg	100	100

BHT: 1% W/V used for all formulations. <sup>a</sup> EFV: efavirenz; <sup>b</sup> SLC: soya lecithin; <sup>c</sup> CHL: cholesterol.

rpm. After a few minutes, the organic solvent was evaporated, and a uniform thin film was formed.<sup>29</sup> The RBF was then kept in a vacuum desiccator overnight for complete evaporation of the solvent. Then, PBS pH 7.4 was transferred to the RBF and hydrated at 40 °C in an RVE.<sup>33,34</sup> After complete dispersion, the mixture was placed in a bath sonicator (Digital Ultrasonic Cleaner, LMUC-3, Labman Scientific Instrument, Chennai, India) for 1 h and kept at room temperature. Then the whole preparation was preserved at 4 °C overnight. Next, this dispersion was then centrifuged using a refrigerated high-speed centrifuge (Z32HK, Hermle Labortechnik, Wehingen, Germany) at 16 000 rpm for 45 min and then lyophilized using a lyophilizer (CoolSafe 4-15L Freeze Dryers, Labogene™, Denmark) to get a dried liposomal product.<sup>35,36</sup>

**Preparation of liposomes containing EFV co-crystals.** In an RBF, CHL, SLC, and BHT were dissolved in chloroform. An equivalent amount of drug co-crystals was added to the solution. Then the previous method was followed to get a dried liposomal product.

**Thermal analysis.** Differential scanning calorimetry (DSC) thermograms of the pristine EFV, L-proline, EFV-L-proline co-crystal, and liposomes containing co-crystals were recorded by using a DSC2A-00831 (TA Instruments, USA). First, about 2 to 3 mg of each sample was placed in a crimped and non-hermetic aluminium pan and run at a heating rate of 10 °C  $\text{min}^{-1}$  in the temperature range of 30–300 °C under a continuous purged dry nitrogen gas flux of 20 mL  $\text{min}^{-1}$ . All the data obtained were analyzed by using Origin software (version 8.5).

### Characterization of experimental liposome batches

**Percentage of yield (% yield).** The yield value is important to calculate the total amount of liposomes obtained out of the total amount of raw ingredients used initially for the formulations. After creating a batch, the lyophilized formulations were weighed, and the yield (percent) was estimated using the equation given below:<sup>37</sup>

$$\text{Percentage yield} = \frac{\text{Weight of liposome obtained}}{\text{Total weight of drug and excipients used in the formulation}} \times 100$$

**Surface morphology study by scanning electron microscopy (SEM).** SEM study was used to evaluate the surface mor-



phology, shape, and size of the optimized liposomal formulations. The freshly prepared formulation was placed onto the carbon adhesive tape on a metallic stub. Then, it underwent gold coating of a thickness of 4 nm, and the coated sample was vacuum dried and examined under SEM (JSM-IT 100, JEOL Ltd, Tokyo, Japan).<sup>38</sup>

**Particle size distribution study.** A particle size analyser (Litesizer 500, Anton Paar, Austria) was used to evaluate the average liposomal vesicle size, vesicle size distribution and polydispersity index (PDI) of all experimental formulations at 25 °C using the standard technique for analysis.<sup>28</sup> The particle size distribution of the formulations was measured by the dynamic light scattering (DLS) principle.<sup>39</sup>

**Zeta potential measurement.** Zeta potential is a measure of the magnitude of the electrostatic or charge repulsion or attraction between particles in a liquid suspension. It is one of the parameters which affect the dispersion stability. The zeta potential of the formulation was also measured by the particle size analyzer (Litesizer 500). The zeta potential of particles and macromolecules in solution was measured by the electrophoretic light scattering (ELS) principle.<sup>28</sup>

**Drug loading and entrapment efficiency study.** Accurately 2 mg of the freeze-dried formulation was weighed and taken in a 2 ml microcentrifuge tube, followed by the addition of 2 ml of acetonitrile–water (7 : 3 v/v) solvent mixture and mixing with a vortex mixer. The dispersion was then sonicated for 2 hours in a bath sonicator before being centrifuged for 10 min at 15 000 rpm in a cold centrifuge. The absorbance of the supernatant solution was measured in a UV-visible spectrophotometer against the acetonitrile–water (7 : 3) mixture as the blank solution at the  $\lambda_{\max}$  of EFV. The % loading of EFV was calculated using the equation below:<sup>40</sup>

$$\begin{aligned} \% \text{ Drug loading} &= \frac{\text{Amount of efavirenz in liposome}}{\text{Amount of liposome obtained}} \times 100 \end{aligned}$$

$$\begin{aligned} \% \text{ Entrapment efficiency} &= \frac{\text{Practical \% drug loading}}{\text{Theoretical \% drug loading}} \times 100 \end{aligned}$$

**In vitro release of EFV from liposomal vesicles.** The drug release study was performed *in vitro* using the dialysis bag method in PBS, pH 7.4<sup>41,42</sup> as the release medium for 7 days. Accurately weighed quantities of EFV-loaded liposomes (2 mg) and EFV co-crystal loaded liposomes were taken separately in pre-labelled microcentrifuge tubes (2 ml) and were suspended in PBS, pH 7.4. Then the dispersion was filled in a dialysis bag (Himedia dialysis membrane-60, Mumbai, India) (molecular weight cut off 12–14 kDa) immediately, and this membrane bag was immersed in PBS, pH 7.4 in a glass beaker and the time was noted as zero. The whole system was kept centrally using a glass rod and covered with aluminum foil to prevent the evaporation of water. This beaker was kept in a thermostatically controlled magnetic stirrer (Aluminium Alloy Cole-Parmer, Advanced Digital Stirring Hot Plates, ColeParmer, India), and the temperature was kept at 37 °C, monitored

using a thermometer at regular time intervals with mild shaking using a magnetic bead rotated at 120 rpm. With the use of a micropipette, 1 ml of drug release media was removed and replaced by fresh PBS at various specified time intervals for 168 h. The absorbance of EFV was measured in a UV-Vis spectrophotometer at a wavelength of maximum absorbance ( $\lambda_{\max}$ ).<sup>43</sup> The drug release data were plotted as cumulative percentage drug release (%CDR) against time in hours.

**Release kinetics.** The release behavior of the formulations was predicted using some appropriate mathematical models such as Zero order, First order, Higuchi model, Hixson–Crowell model, and Korsmeyer–Peppas model. Multiple models were fitted to the data to predict the mechanism of drug release.<sup>44–46</sup>

**Stability study.** The stability study was performed in accordance with ICH guidelines. The dried liposomal formulations were subjected to stability studies for 3 months at 4 °C. The optimized formulation was tested for physical appearance and zeta potential 1 month and 3 months after the formulation was made.<sup>47</sup>

**Statistical analysis.** All the experiments were conducted in triplicate and data were presented as average  $\pm$  standard deviation (SD).

## Results and discussion


### FTIR spectroscopy

FTIR spectroscopy is a useful method for identifying the functional groups present in chemicals used in formulations.<sup>29</sup> Hence, any changes in the functional group may indicate the presence of interaction. In this study, FTIR spectra of pure drug EFV, L-proline, and EFV co-crystals were recorded and are presented in Fig. 1.

The pure drug EFV showed a strong N–H stretching at 3320  $\text{cm}^{-1}$ , C=O stretching at 1749  $\text{cm}^{-1}$ , C–C stretching due to the alkyne group at 2250  $\text{cm}^{-1}$ , C–F stretching at 1317  $\text{cm}^{-1}$  and 1242  $\text{cm}^{-1}$ , C–Cl stretching at 1039  $\text{cm}^{-1}$ , and C–O–C stretching at 1074  $\text{cm}^{-1}$  and 1098  $\text{cm}^{-1}$ . The characteristic peaks of EFV for C=C stretching of the aromatic ring were observed at 1602  $\text{cm}^{-1}$  and 1496  $\text{cm}^{-1}$ , and the peak for C–H stretching was also observed at 2925  $\text{cm}^{-1}$ .<sup>12</sup> The distinctive peaks of L-proline were observed at 1623, 2348, and 3486  $\text{cm}^{-1}$ , representing C=O stretching of the carboxylic acid, N–H stretching of the amine heterocyclic ring, and O–H stretching of the carboxylic acid, respectively.<sup>48</sup> FTIR spectra of EFV cocrystals showed characteristics peaks of L-proline and pure EFV with some changes due to the formation of hydrogen bonds between the components. It showed peaks at 1621  $\text{cm}^{-1}$  and 1753  $\text{cm}^{-1}$  for C=O and 2363  $\text{cm}^{-1}$  and 3433  $\text{cm}^{-1}$  for N–H and O–H groups, respectively. It showed strong intensity at 2248  $\text{cm}^{-1}$  for the C–C group. For the C–F group, it showed peaks at 1311 and 1242  $\text{cm}^{-1}$ . Peaks at 1025 and 1497  $\text{cm}^{-1}$  confirmed the presence of C–Cl and C=C groups.<sup>18,19</sup>

FTIR spectra of SLC, CHL, the physical mixture of EFV, CHL, and SLC, and the physical mixture of EFV cocrystals, CHL, and SLC are reported in Fig. 1. The FTIR spectra of SLC revealed characteristic peaks at 2925  $\text{cm}^{-1}$  for C–H stretching,





**Fig. 1** FTIR spectra of pure efavirenz (EFV); L-proline; EFV cocrystal; lecithin; cholesterol (CHL); physical mixture of EFV, lecithin and CHL; physical mixture of EFV co-crystal, lecithin, and CHL; EFV-loaded liposomes; and EFV co-crystal-loaded liposomes.

at  $1725\text{ cm}^{-1}$  for strong intensity of C=O stretching vibration, at  $1350\text{ cm}^{-1}$  for medium intensity of C–O stretching vibration, and at  $1050\text{ cm}^{-1}$  for C–O groups (glycerol) and C–N groups (choline) present in lecithin.<sup>34</sup> CHL showed a peak at  $3590\text{ cm}^{-1}$  due to the presence of the –OH group and a strong intensity band at  $2930\text{ cm}^{-1}$  due to C–H stretching as well as at  $2850\text{ cm}^{-1}$  due to C–OH stretching. CHL showed its characteristic strong intensity stretching vibration of C–O at  $1054\text{ cm}^{-1}$ .<sup>49</sup> FTIR spectra of the physical mixture containing the drug, SLC, and CHL showed the individual peaks of components, which confirmed that the drug did not undergo any chemical interaction with the excipients present. Again, the FTIR spectra of the physical mixture containing co-crystals, SLC and CHL showed the individual peaks of components, which confirmed that the co-crystals did not undergo any chemical interaction with the excipients present.

The FTIR spectra of liposome formulations containing pure EFV and EFV cocrystals are shown in Fig. 1. The spectrum of EFV-loaded liposomes showed some characteristic peaks of EFV in the same spectral regions, in addition to peaks due to the lipid components that appeared at  $2931\text{ cm}^{-1}$  and  $1466\text{ cm}^{-1}$  for the alkane C–H stretching, at  $1242\text{ cm}^{-1}$  for the ester sigma bonds and at  $1107\text{ cm}^{-1}$  for the ether region.<sup>50</sup>

The spectrum of co-crystal loaded liposomes contains the characteristic peaks of EFV co-crystals, L-proline, and other components. It showed a peak at  $2929\text{ cm}^{-1}$  for the lipid component, at  $1242\text{ cm}^{-1}$  and  $1317\text{ cm}^{-1}$  for C–F stretching, at  $1632\text{ cm}^{-1}$  and  $1750\text{ cm}^{-1}$  for C=O stretching, at  $2250\text{ cm}^{-1}$  for C–C stretching, and at  $1496\text{ cm}^{-1}$  for C=C stretching.

### pXRD analysis

The p-XRD data for pristine EFV, L-proline, and EFV co-crystals with L-proline are represented in Fig. 2. Fig. 2A exhibits some sharp characteristic peaks ( $2\theta$ ) at  $6.24^\circ$ ,  $10.94^\circ$ ,  $12.74^\circ$ ,  $13.59^\circ$ ,

$14.69^\circ$ ,  $16.92^\circ$ ,  $20.69^\circ$ ,  $21.74^\circ$ ,  $25.39^\circ$ ,  $28.59^\circ$  and  $39.19^\circ$ , which may be attributed to the presence of crystalline character of EFV in its pure form.

Pure L-proline shows characteristic peaks at  $15.39^\circ$ ,  $18.29^\circ$ ,  $19.74^\circ$ ,  $22.89^\circ$ ,  $24.89^\circ$ ,  $30.69^\circ$ ,  $32.34^\circ$ ,  $35.14^\circ$ ,  $36.79^\circ$ ,  $39.99^\circ$  and  $43.69^\circ$ . However, the p-XRD pattern of co-crystals exhibits a significant difference as compared to the characteristic peak of pristine EFV and L-proline. It suggests the formation of a new crystalline phase.


### Solubility study of co-crystals

The  $\lambda_{\text{max}}$  of efavirenz was determined and found to be  $247.5\text{ nm}$ . In the aqueous solubility study of EFV and its co-crystals, the result revealed that the solubility of pure EFV was  $5.46\text{ }\mu\text{g ml}^{-1}$  and that of EFV co-crystals with L-proline (equimolar) was  $15.01\text{ }\mu\text{g ml}^{-1}$ , which suggests a 3 fold improvement in the solubility of co-crystals compared to pure drug. This is because of the salification where a hydrogen bond donor group leads to an association with an acceptor group. A hydrogen bond was formed between the –N–H and –C=O functional groups of L-proline.<sup>19</sup> The –N–H band of EFV has broadened, with a considerable shift towards higher wavenumber from  $1749\text{ cm}^{-1}$  to  $1753\text{ cm}^{-1}$  (redshift) in the case of co-crystals, which actually occurred due to the involvement of intermolecular interactions such as hydrogen bonding. Due to the enhancement of solubility as a result of co-crystal formation, the dissolution profile of the drug can also be increased.<sup>17</sup>

### DSC analysis

The DSC patterns are given in Fig. 3. The two endothermic peaks observed for pure L-proline that were close to one another were assigned to the melting of L-proline accompanied by decomposition, and it was similar to an observation by





**Fig. 2** X ray diffraction pattern of (A) pristine efavirenz, (B) L-proline and (C) cocrystals of efavirenz with L-proline.

another study.<sup>51</sup> The onset and peak temperatures of L-proline were 232 and 234 °C, respectively. The DSC of pure EFV showed a sharp endothermic peak at 138 °C. EFV co-crystals with L-proline showed an endothermic peak at 266 °C and 126 °C, which exhibits a unique and distinct melting endotherm compared to the EFV and L-proline, which confirms the formation of a new crystalline phase. Earlier studies reported that the formation of co-crystals with lower melting points and lower enthalpy value implies an increased dissolution rate compared to the parent compound.<sup>18</sup> The liposomes encapsulated with co-crystals showed none of the endothermic peaks, suggesting the complete encapsulation of the co-crystal within the liposome core.

### Percentage yield of liposomes

The yield percentage of different batches was determined after the formulation of different batches to know the amount of liposomes recovered in each batch.<sup>52,53</sup> The percentage yield of

liposomes containing co-crystals is more than that of the liposomes containing pure drugs (Table 2). The maximum yield was observed in the F6 batch.

### Drug loading and entrapment efficiency study

The  $\lambda_{\max}$  value of EFV in the acetonitrile water mixture was found to be 247 nm. Drug loading and entrapment efficiency of the formulation batches were determined, and the drug loading values of the F1, F2, F3, F4, F5, and F6 batches were found to be 28.41%, 31.00%, 24.40%, 36.62%, 29.98%, and 32.70%, respectively. The entrapment efficiency of the F1, F2, F3, F4, F5, and F6 formulations was found to be 56.82%, 63.10%, 61.26%, 92.86%, 89.97% and 99.28%, respectively (Table 2). The encapsulation efficiency augmented as the amount of CHL incorporated into the liposomes increased.<sup>54</sup> The formulation with the highest entrapment efficiency contained 100 mg of SLC and CHL individually.

### Particle size, PDI and zeta potential of liposomes

Particle size, PDI and zeta potential were measured with the particle size analyzer instrument using the software KALLIOPÉ<sup>PM</sup>, which used the principle of dynamic light scattering. Particle size and zeta potential of the experimental formulation batches (F1–F6) are given in Table 3.


The particle size of the liposomes was in a range of 300–440 nm. Fig. 4 shows the narrow size range of the experimentally developed liposomes for both F5 and F6. Here, we can see that with an increase in the amount of CHL, the particle size of the liposomal vesicles increased. F5 and F6 are considered optimal batches because the particle size of these batches is larger but in the range of standard size of liposomal vesicles (usually 50–500 nm in diameter).<sup>26</sup> PDI values of all formulations were found to be below 38% or 0.38. A PDI value less than 0.3 is considered to be satisfactory and indicates a homogeneous distribution of phospholipid vesicles.<sup>55</sup> The optimal formulations F5 and F6 had PDI values of 29.1 and 21.3, respectively.

Depending on the composition, the zeta potential of the liposomes can be positive, neutral, or negative. It affects the physical stability (aggregation) and *in vivo* behavior of the formulation. Generally, the zeta potential of liposomes is negative due to the presence of carboxylic groups in lipids.<sup>36</sup> A zeta potential less than –30 mV or greater than +30 mV is considered to be stable in colloidal form for a prolonged period and prevents settling down while in suspension.<sup>36,56</sup> Here we can see that all formulations had zeta potential less than –30 mV (Fig. 4C and D), which means that the surface charge of the prepared liposomes was negative and the vesicles were stable in colloidal form.<sup>56</sup> Based on the particle size, zeta potential, drug loading, and entrapment efficiency data, formulation batches F5 and F6 were found to be optimal batches and selected for further studies.

### Study of surface morphology of liposomes by SEM

SEM images of the freshly prepared optimized formulations (F5 and F6) revealed that the prepared liposomes had a





**Fig. 3** DSC thermogram of pristine efavirenz, L-proline, cocrystals of efavirenz with L-proline, and liposomal formulation containing cocrystals of efavirenz.

**Table 2** Formulation outcome, %yield, drug loading, and entrapment efficiency of the formulations

Formulation code	% yield	Practical drug loading (%)	Theoretical drug loading (%)	Entrapment efficiency (%)
F1	23.67 ± 2.77	28.41	50.00	56.82 ± 3.30
F2	51.20 ± 1.04	31.00	49.14	63.10 ± 1.51
F3	44.25 ± 1.54	24.50	40.00	61.26 ± 3.72
F4	67.78 ± 6.74	36.62	39.44	92.86 ± 2.08
F5	53.98 ± 1.02	29.98	33.33	89.97 ± 2.16
F6	72.28 ± 0.80	32.70	32.94	99.28 ± 1.05

**Table 3** Particle size, polydispersity index (PDI) and zeta potential values of the experimental liposome batches

Formulation code	Particle size (nm) ± SD	PDI (%)	Zeta potential (mV) ± SD
F1	333 ± 0.12	22.5	-48.82 ± 1.21
F2	342 ± 12.26	19.9	-53.85 ± 0.21
F3	408 ± 13.86	36.0	-36.80 ± 0.90
F4	425 ± 4.89	37.1	-46.30 ± 1.00
F5	411 ± 7.40	29.1	-41.10 ± 1.00
F6	437 ± 84.80	21.3	-43.53 ± 0.86

smooth surface and spherical shape and average sizes of the liposomes were found to be around 300–400 nm with a thick dense distribution. The SEM images of formulation batches F5 and F6 are given in Fig. 5.

The formulation F5 containing the pure drug (Fig. 5A and B) had distinct spherical particles with uniform sizes compared to other formulations, and most particles were below 500 nm. The formulation F6 containing EFV-cocrystals (Fig. 5C and D) showed spherical particles of the range 300–450 nm, obtained from visual estimation.

SEM images of the freshly prepared optimized formulations (F5 and F6) revealed more homogeneous distribution of the nanoliposomes, and the size of the liposomal vesicles was found to be within 400 nm, which is smaller than those detected in DLS. The difference in size may be due to the DLS method measuring the hydrodynamic diameter, and while preparing the sample in double distilled water, the liposomal formulation may swell, increasing the size.<sup>57</sup>

#### *In vitro* drug release study

On the basis of drug loading, particle size and SEM study, F5 and F6 formulation batches were found to be the best based on the parameters investigated and considered for the release study experiment. This study was performed in PBS pH 7.4 at 247 nm maximum wavelength. The linear graph had a regression coefficient value of 0.998 with a slope of 0.026. A distinct enhancement in EFV release was obtained in the *in vitro* drug release testing of plain EFV loaded liposomes as compared to liposomes containing EFV co-crystals as shown in Fig. 6. The increase in drug release can be attributed to the formation of hydrogen bonding between the -N-H and -C=O functional groups of L-proline.<sup>19</sup> Similar data were seen in lipo-






Fig. 4 Particle size distribution of (A) the F5 batch and (B) F6 batch; zeta potential of (C) the F5 batch and (D) F6 batch.





Fig. 5 SEM images of pure EFV loaded liposomes (F5) measured at (A) 1700x and (B) 9000x magnification and EFV cocrystal-loaded liposomes (F6) measured at (C) 5000x and (D) 6000x magnification.

some prepared with EFV.<sup>50</sup> The release data of EFV showed that the drug had limited solubility in its pure form and in the liposomal state, the release was modified in the presence of pluronic F127 in addition to carbopol in biofilm.<sup>58</sup> In both

batches, F5 and F6, the drug was released in two clear phases: the first phase with burst release of the drug and the 2nd phase with sustained drug release. The liposomes containing the pure drug showed burst release of the drug until 2 h and







**Fig. 6** Percentage cumulative release of efavirenz in PBS (pH 7.4) medium from optimized F5 and F6 batches with respect to time (data represented as  $n = 3$ , mean  $\pm$  SD).

sustained release up to 168 h, while the liposomes containing co-crystals showed burst release until 1 h and sustained release up to 72 h. The drug release of liposomes containing the co-crystals of EFV (F6) was found to be 99.98% in 72 hours, whereas the drug release of liposomes containing plain EFV (F5) was found to be 72%. The presence of L-proline in association with EFV leads to an enhancement in the polarity of hydrophobic EFV, thus increasing its dissolution in dissolution media. Thus, the cumulative drug release is more in the case of F6 than the batch F5.

### Release kinetics

The drug release data have been tested by plotting them in different kinetic models (zero order, first order, Higuchi model, Hixson–Crowell Model, and Korsmeyer–Peppas model), and the data are given in Table 4. Zero order and first order

**Table 4** Data of drug release kinetics in various kinetic models

Sample	Kinetic model	Equation	$R^2$ value
F5 batch	Zero order	$y = 0.540x + 19.120$	$R^2 = 0.900$
	First order	$y = -0.008x + 1.955$	$R^2 = 0.928$
	Higuchi model	$y = 7.203x + 7.052$	$R^2 = 0.992$
	Korsmeyer–Peppas	$y = 0.399x + 1.101$	$R^2 = 0.993$
	Hixson–Crowell	$y = -0.017x + 4.383$	$R^2 = 0.975$
F6 batch	Zero order	$y = 1.338x + 20.398$	$R^2 = 0.829$
	First order	$y = -0.021x + 1.947$	$R^2 = 0.993$
	Higuchi model	$y = 12.037x + 6.007$	$R^2 = 0.984$
	Korsmeyer–Peppas	$y = 0.454x + 1.214$	$R^2 = 0.994$
	Hixson–Crowell	$y = -0.056x + 4.428$	$R^2 = 0.985$

**Table 5** Stability study data of optimized batches

	Time period	Particle size (nm)	Zeta potential (mV)	%Drug loading
F5 batch	Fresh formulation	411.10 $\pm$ 7.40	-41.1 $\pm$ 1.0	29.98 $\pm$ 0.31
	After 1 month	415.23 $\pm$ 0.7	-39.9 $\pm$ 0.7	29.97 $\pm$ 0.40
	After 3 months	413.11 $\pm$ 1.0	-38.0 $\pm$ 0.4	29.97 $\pm$ 0.83
F6 batch	Fresh formulation	437.4 $\pm$ 84.80	-43.53 $\pm$ 0.86	32.72 $\pm$ 0.30
	After 1 month	441.3 $\pm$ 22.4	-40.43 $\pm$ 2.53	32.70 $\pm$ 0.48
	After 3 months	440.42 $\pm$ 38.1	-30.79 $\pm$ 30	32.71 $\pm$ 1.14

kinetics only depict whether the drug release is concentration independent or dependent. Zero order release kinetics of a drug is only a function of time. First-order reaction kinetics showed that the drug release mechanism is concentration dependent. Hence, the amount of drug release lessened with decreasing concentration gradient over time.<sup>59</sup> The Higuchi kinetic model describes the drug release from a matrix type system. This model is followed when the matrix is swelled by the solvent and the concentration gradient becomes linear and is decreasing from the saturated concentration at the interface with the core.<sup>60</sup> The Korsmeyer–Peppas kinetic model is used to describe drug release following non-Fickian mechanisms from a polymeric matrix. The mechanism depends on the Korsmeyer–Peppas release exponent (or “ $n$ ” value). When  $n < 0.5$ , the drug diffuses by the Fickian diffusion mechanism. When  $n$  is equal to 0.89, the case II transport mechanism prevails and an  $n$  value  $> 0.89$  describes the super case II transport mechanism. When the  $n$  value lies between 0.5 and 0.9, a non-Fickian release mechanism with anomalous diffusion is considered.<sup>59,61</sup> The Hixson–Crowell cube root law specifically correlates the drug release rate from the systems made of polymers which erode over time from the exposed surface. This model depends on the change in surface area and diameter of the particles.<sup>62</sup>

The maximum linearity (as assumed by  $R^2$  values) was observed for the Korsmeyer Peppas model (Table 4). For the F5 batch, the regression coefficient ( $R^2$  value) is 0.993, and for the F6 batch, it is 0.994. The release exponent ( $n$ ) is used to characterize the release mechanism of the drug. For both batches (F5 and F6), the  $n$  value is less than 0.5, which indicates the Fickian release mechanism (Fig. S1 and S2 of ESI†).

### Stability studies

The stability of selected batches F5 and F6 was assessed over a period of 3 months. No significant color changes were observed in the liposomes. The mean values of particle size, zeta potential, and drug loading of fresh formulations were compared to those of formulations stored for 1 month and 3 months (Table 5). The particle size and zeta potential remained almost constant over the storage period. The zeta potential results indicated the good stability of the experimental formulations as only a negative charge can prevent the emulsion from cracking and phase separation. The percentage drug loading also remained almost constant after 3 months, indicating the stability of the stored formula. The unchanged physical appearance, size, and zeta potential of the liposome



vesicles are supported indicators of kinetically stable formulation redispersed in water in suspended form.

## Conclusion

In the present study, liposomes encapsulating EFV co-crystals were prepared using L-proline as a cofomer, particularly focusing on the anti-HIV action of the drug. The drug EFV belongs to BCS class II, having poor water solubility and high permeability. Due to the solubility problem, the bioavailability of the drug is very less. Here, we developed co-crystals to increase the solubility up to 3 fold and co-crystal entrapped liposomes to release the drug in a sustained manner. The formation of cocrystals of EFV was confirmed by XRD and DSC analysis. The optimized formulation was found to have a substantial amount of EFV loading (32.70%) and entrapment efficiency (99.28%) with a standard range of size distribution. The drug release study was performed for the pure drug containing liposomes and co-crystal containing liposomes, and both formulations were released in two clear phases: the first phase with burst release and the 2nd phase with sustained release. The liposomes containing the pure drug showed 72% release of the drug in 72 h, while the liposomes containing co-crystals showed 99.98% release of the drug in 72 h. This is due to the presence of L-proline in association with EFV, which leads to an enhancement in the polarity of hydrophobic EFV, thus increasing its dissolution in dissolution media. The sustained release minimizes the frequency of dosing. Other studies, including zeta potential, SEM, and FTIR studies, were done to confirm the stability of the formulations, spherical shape of liposomes, and compatibility of the components, respectively. To date, co-crystal-loaded liposomes have not been reported, and this is the first time we are following this approach to deliver EFV for antiretroviral therapy with much better therapeutic efficacy in markedly reduced doses.

## Data availability

The study's original contributions are accessible in the article, and additional inquiries can be directed to the corresponding author.

## Conflicts of interest

The authors declare to have no financial or non-financial conflicts of interest.

## Acknowledgements

This work reports no funding. The authors sincerely acknowledged the indebted support, e-resources, and infrastructural facilities provided by the University of North Bengal, Darjeeling. The authors further acknowledge Central instru-

mentation facility of BIT Mesra, Ranchi for performing DSC analysis.

## References

- 1 E. Ojewole, I. Mackraj, P. Naidoo and T. Govender, *Eur. J. Pharm. Biopharm.*, 2008, **70**, 697–710.
- 2 T. Melis, T. Sahle, K. Haile, A. Timerga, A. Zewdie, Y. Wegu, K. Zepire and J. Bedewi, *J. Pharm. Policy Pract.*, 2024, **17**, 2290672.
- 3 T. C. Quinn, M. J. Wawer, N. Sewankambo, D. Serwadda, C. Li, F. Wabwire-Mangen, M. O. Meehan, T. Lutalo and R. H. Gray, *N. Engl. J. Med.*, 2000, **342**, 921–929.
- 4 J. M. Baeten, E. Kahle, J. R. Lingappa, R. W. Coombs, S. Delany-Moretwe, E. Nakku-Joloba, N. R. Mugo, A. Wald, L. Corey and D. Donnell, *Sci. Transl. Med.*, 2011, **3**, 77ra29–77ra29.
- 5 J.-A. Röttingen, D. W. Cameron and G. P. Garnett, *Sex. Transm. Dis.*, 2001, 579–597.
- 6 Q. Le Hingrat, I. Sereti, A. L. Landay, I. Pandrea and C. Apetrei, *Front. Immunol.*, 2021, **12**, 695674.
- 7 F. E. T. Foka and H. T. Mufhandu, *Viruses*, 2023, **15**, 1732.
- 8 M. Ullah Nayan, B. Sillman, M. Hasan, S. Deodhar, S. Das, A. Sultana, N. Thai Hoang Le, V. Soriano, B. Edagwa and H. E. Gendelman, *Adv. Drug Delivery Rev.*, 2023, **200**, 115009.
- 9 S. SeyedAlinaghi, A. M. Afsahi, A. Moradi, Z. Parmoon, P. Habibi, P. Mirzapour, M. Dashti, A. Ghasemzadeh, E. Karimi, F. Sanaati, Z. Hamed, A. Molla, E. Mehraeen and O. Dadras, *AIDS Res. Ther.*, 2023, **20**, 74.
- 10 B. Yavuz, J. L. Morgan, L. Showalter, K. R. Horng, S. Dandekar, C. Herrera, P. LiWang and D. L. Kaplan, *Adv. Ther.*, 2018, **1**, 1800054.
- 11 M. H. Dinh, M. R. Anderson, M. D. McRaven, G. C. Cianci, S. G. McCoombe, Z. Kelley, C. J. Gioia, A. J. Fought, A. W. Rademaker and R. S. Veazey, *PLoS Pathog.*, 2015, **11**, e1004729.
- 12 P. K. Gaur, S. Mishra, M. Bajpai and A. Mishra, *BioMed Res. Int.*, 2014, **2014**, 363404.
- 13 S. Velmurugan, M. A. Ali and P. Kumar, *Int. J. Pharm. Pharm. Sci.*, 2014, **6**, 31–39.
- 14 A. Carr and D. A. Cooper, *Lancet*, 2000, **356**, 1423–1430.
- 15 L. N. Ramana, A. R. Anand, S. Sethuraman and U. M. Krishnan, *J. Controlled Release*, 2014, **192**, 271–283.
- 16 M. Guo, X. Sun, J. Chen and T. Cai, *Acta Pharm. Sin. B*, 2021, **11**, 2537–2564.
- 17 B. J. Gowda, S. K. Nechipadappu, S. Shankar, M. Chavali, K. Paul, M. G. Ahmed, A. Sanjana and H. Shanthala, *Mater. Today: Proc.*, 2022, **51**, 394–402.
- 18 B. J. Gowda, M. G. Ahmed, S. Shankar, K. Paul, R. Chandan, A. Sanjana, S. Narayana, A. Nasrine, N. Noushida and M. Thriveni, *Mater. Today: Proc.*, 2022, **57**, 878–886.



- 19 P. M. Szell, J. R. Lewandowski, H. Blade, L. P. Hughes, S. O. N. Lill and S. P. Brown, *CrystEngComm*, 2021, **23**, 6859–6870.
- 20 I. Nugrahani, D. Utami, S. Ibrahim, Y. P. Nugraha and H. Uekusa, *Eur. J. Pharm. Sci.*, 2018, **117**, 168–176.
- 21 P. Prajapati, J. Pandey, P. Tandon, K. Sinha and M. R. Shimpi, *Front. Chem.*, 2022, **10**, 848014.
- 22 E. Parhizkar, M. Rashedinia, M. Karimi and S. Alipour, *J. Microencapsulation*, 2018, **35**, 301–311.
- 23 V. Kenchappa, R. Cao, V. Venketaraman and G. V. Betageri, *Appl. Sci.*, 2022, **12**, 1468.
- 24 A. R. Mohammed, N. Weston, A. G. A. Coombes, M. Fitzgerald and Y. Perrie, *Int. J. Pharm.*, 2004, **285**, 23–34.
- 25 H. Liang, F. Zou, Q. Liu, B. Wang, L. Fu, X. Liang, J. Liu and Q. Liu, *Int. J. Pharm.*, 2021, **599**, 120418.
- 26 H. Nsairat, D. Khater, U. Sayed, F. Odeh, A. Al Bawab and W. Alshaer, *Heliyon*, 2022, **8**, e09394.
- 27 M. D. Fulton and W. Najahi-Missaoui, *Int. J. Mol. Sci.*, 2023, **24**, 6615.
- 28 J. Douda, L. G. Miranda Calderón, T. Kryshtab, J. S. Arias Cerón and A. Kryvko, *J. Mater. Sci.: Mater. Electron.*, 2018, **29**, 15570–15578.
- 29 B. Han, Y. Yang, J. Chen, H. Tang, Y. Sun, Z. Zhang, Z. Wang, Y. Li, Y. Li and X. Luan, *Int. J. Nanomed.*, 2020, 553–571.
- 30 F. H. Blindheim and J. Ruwoldt, *Polymers*, 2023, **15**, 2901.
- 31 V. Rajurkar, N. Sunil and V. Ghawate, *Med. Chem.*, 2015, **2**, 2161–2444.
- 32 T. A. Ahmed, A. O. Bawazir, W. S. Alharbi and M. K. Safo, *Int. J. Nanomed.*, 2020, **15**, 4001–4020.
- 33 L. Dutta, B. Mukherjee, T. Chakraborty, M. K. Das, L. Mondal, S. Bhattacharya, R. H. Gaonkar and M. C. Debnath, *Drug Delivery*, 2018, **25**, 504–516.
- 34 A. Mallick, R. Sahu, G. Nandi, T. K. Dua, T. K. Shaw, A. Dhar, A. Kanu and P. Paul, *J. Pharm. Innovation*, 2023, **18**, 1020–1029.
- 35 S. Sengupta, P. Paul, B. Mukherjee, R. H. Gaonkar, M. C. Debnath, R. Chakraborty, N. Khatun and S. Roy, *Nanomedicine*, 2018, **13**, 3009–3023.
- 36 S. Satapathy and A. Naik, *Complex Intell. Syst.*, 2016, **2**, 173–203.
- 37 N. S. Dey, B. Mukherjee, R. Maji and B. S. Satapathy, *Curr. Cancer Drug Targets*, 2016, **16**, 357–372.
- 38 D. E. Large, R. G. Abdelmessih, E. A. Fink and D. T. Auguste, *Adv. Drug Delivery Rev.*, 2021, **176**, 113851.
- 39 F. Weber, L. Rahnfeld and P. Luciani, *Talanta*, 2020, **220**, 121320.
- 40 P. Paul, S. Sengupta, B. Mukherjee, T. K. Shaw, R. H. Gaonkar and M. C. Debnath, *Nanomedicine*, 2018, **13**, 501–520.
- 41 S. Kakad and S. Kshirsagar, *Heliyon*, 2021, **7**, e08368.
- 42 P. K. Gaur, S. Mishra, M. Bajpai and A. Mishra, *BioMed Res. Int.*, 2014, **2014**, 363404.
- 43 R. Kumar and V. Sinha, *AAPS PharmSciTech*, 2017, **18**, 884–894.
- 44 C. Cheng, Z. Wu, D. J. McClements, L. Zou, S. Peng, W. Zhou and W. Liu, *Colloids Surf., B*, 2019, **183**, 110460.
- 45 S. Das, A. Samanta, S. Mondal, D. Roy and A. K. Nayak, *Sens. Int.*, 2021, **2**, 100077.
- 46 K. Karami, N. Jamshidian, A. Hajiaghahi and Z. Amirghofran, *New J. Chem.*, 2020, **44**, 4394–4405.
- 47 S. Ugwu, A. Zhang, M. Parmar, B. Miller, T. Sardone, V. Peikov and I. Ahmad, *Drug Dev. Ind. Pharm.*, 2005, **31**, 223–229.
- 48 I. Nugrahani, R. A. Kumalasari, W. N. Auli, A. Horikawa and H. Uekusa, *Pharmaceutics*, 2020, **12**, 690.
- 49 A. M. Siddiquee, A. Hourri, K. A. Messalea, J. Lin, T. Daeneke, B. Abbey, A. Mechler and S. Kou, *J. Phys. Chem. Lett.*, 2020, **11**, 9476–9484.
- 50 N. I. Okafor, C. I. Nkanga, R. B. Walker, X. S. Noundou and R. W. M. Krause, *J. Pharm. Invest.*, 2020, **50**, 201–208.
- 51 A. Neacsu, D. Gheorghe, C. Marinescu, E. Stancu, V. Tecuceanu and C. Ciuculescu, *Radiat. Phys. Chem.*, 2019, **156**, 115–127.
- 52 M. K. Das and B. Kalita, *J. Appl. Pharm. Sci.*, 2014, **4**, 051–057.
- 53 J. Zhang, Q. Tang, X. Xu and N. Li, *Int. J. Pharm.*, 2013, **448**, 168–174.
- 54 B. S. Pattni, V. V. Chupin and V. P. Torchilin, *Chem. Rev.*, 2015, **115**, 10938–10966.
- 55 M. Danaei, M. Dehghankhold, S. Ataei, F. Hasanzadeh Davarani, R. Javanmard, A. Dokhani, S. Khorasani and M. R. Mozafari, *Pharmaceutics*, 2018, **10**, 57.
- 56 K. Ogurtsova, J. da Rocha Fernandes, Y. Huang, U. Linnenkamp, L. Guariguata, N. H. Cho, D. Cavan, J. Shaw and L. Makaroff, *Diabetes Res. Clin. Pract.*, 2017, **128**, 40–50.
- 57 M. R. Rao and L. S. Babrekar, *Indian J. Pharm. Sci.*, 2018, **80**, 1115–1124.
- 58 N. I. Okafor, M. Ngoepe, X. S. Noundou and R. W. Maçedo Krause, *J. Drug Delivery Sci. Technol.*, 2019, **54**, 101312.
- 59 F. Shafiei, M. Ghavami-Lahiji, T. S. Jafarzadeh Kashi and F. Najafi, *Dent. Res. J.*, 2021, **18**, 94.
- 60 C. Mircioiu, V. Voicu, V. Anuta, A. Tudose, C. Celia, D. Paolino, M. Fresta, R. Sandulovici and I. Mircioiu, *Pharmaceutics*, 2019, **11**, 140.
- 61 N. S. Heredia, K. Vizuete, M. Flores-Calero, V. K. Pazmiño, F. Pilaquinga, B. Kumar and A. Debut, *PLoS One*, 2022, **17**, e0264825.
- 62 M. A. Malana and R. Zohra, *Daru, J. Pharm. Sci.*, 2013, **21**, 10.

